Ligero, C.; Riera, P.; El-Amrani, A.; Bazan, V.; Guerra, J.M.; Herraez, S.; Viñolas, X.; Alegret, J.M.
Impact of Body Mass Index in the Cardioverter Efficacy of Amiodarone in Persistent Atrial Fibrillation. Pharmaceuticals 2024, 17, 693.
https://doi.org/10.3390/ph17060693
AMA Style
Ligero C, Riera P, El-Amrani A, Bazan V, Guerra JM, Herraez S, Viñolas X, Alegret JM.
Impact of Body Mass Index in the Cardioverter Efficacy of Amiodarone in Persistent Atrial Fibrillation. Pharmaceuticals. 2024; 17(6):693.
https://doi.org/10.3390/ph17060693
Chicago/Turabian Style
Ligero, Carmen, Pau Riera, Amine El-Amrani, Victor Bazan, José M. Guerra, Silvia Herraez, Xavier Viñolas, and Josep M. Alegret.
2024. "Impact of Body Mass Index in the Cardioverter Efficacy of Amiodarone in Persistent Atrial Fibrillation" Pharmaceuticals 17, no. 6: 693.
https://doi.org/10.3390/ph17060693
APA Style
Ligero, C., Riera, P., El-Amrani, A., Bazan, V., Guerra, J. M., Herraez, S., Viñolas, X., & Alegret, J. M.
(2024). Impact of Body Mass Index in the Cardioverter Efficacy of Amiodarone in Persistent Atrial Fibrillation. Pharmaceuticals, 17(6), 693.
https://doi.org/10.3390/ph17060693